GLSI
Greenwich Lifesciences Inc
NASDAQ: GLSI · HEALTHCARE · BIOTECHNOLOGY
$21.60
-5.26% today
Updated 2026-04-29
Market cap
$332.37M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.46
Dividend yield
—
52W range
$8 – $34
Volume
0.2M
Greenwich Lifesciences Inc (GLSI) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — |
| Cost of revenue | $3607.00 | $3607.00 | $3607.00 | $3609.00 | $3612.00 | $3612.00 | $3612.00 | $3612.00 |
| Gross profit | $-3607.00 | $-3607.00 | $-3607.00 | $-3609.00 | $-3612.00 | $-3612.00 | $-3612.00 | $-3612.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $1.22M | $1.27M | $2.61M | $1.06M | $3.56M | $6.48M | $7.70M | $12.95M |
| SG&A | — | $419639.00 | $818887.00 | $806188.00 | $1.04M | $1.56M | $1.63M | $3.06M |
| Operating income | $-1.57M | $-1.69M | $-3.43M | $-1.86M | $-4.60M | $-8.04M | $-9.33M | $-16.01M |
| Operating margin | — | — | — | — | — | — | — | — |
| EBITDA | $-1.57M | $-1.69M | $-3.42M | $-1.86M | $-4.59M | $-8.04M | $-9.32M | $-15.79M |
| EBITDA margin | — | — | — | — | — | — | — | — |
| EBIT | $-1.57M | $-1.69M | $-3.43M | $-1.86M | $-4.60M | $-8.04M | $-9.33M | $-15.79M |
| Interest expense | — | $0.00 | $0.00 | $0.00 | $27367.00 | $215017.00 | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-1.57M | $-1.69M | $-3.43M | $-1.86M | $-4.57M | $-7.83M | $-8.89M | $-15.79M |
| Net income growth (YoY) | — | -7.4% | -102.7% | +45.6% | -145.4% | -71.2% | -13.6% | -77.6% |
| Profit margin | — | — | — | — | — | — | — | — |